Oxidative modification of nicotinamide nucleotide transhydrogenase in submitochondrial particles: effect of endogenous ubiquinol.
The present paper describes the sensitivity of the mitochondrial nicotinamide nucleotide transhydrogenase (EC 1.6.1.1) to oxidative modification, and the effects of endogenous ubiquinol on this modification. A comparison is made between the effects of treatment with ADP-Fe3+ and ascorbate and with peroxynitrite, using kinetic, electrophoretic, and immunological analyses, together with lipid peroxidation measurements. The transhydrogenase was inactivated by both types of oxidative modification, but apparently through different mechanisms. Ubiquinol protected the enzyme against inactivation only when the modification was caused by ADP-Fe3+ and ascorbate treatment. Kinetic measurements revealed a threefold increase of the Km value of the enzyme for NADPH after exposure to ADP-Fe3+ and ascorbate, and a twofold increase of the Km values for both NADH and NADPH after exposure to peroxynitrite. NAD(H) exerted a protection against trans-hydrogenase inactivation when added to the preincubation in the case of peroxynitrite, but neither NAD(H) or NADP(H) protected in the case of ADP-Fe3+ and ascorbate. Using immunoblotting it was shown that the enzyme became both aggregated and fragmented, although to different extents, depending on the oxidative system used. Again, ubiquinol prevented these effects only in the case of ADP-Fe3+ and ascorbate treatment. Furthermore, there occurred a striking decrease in the 66-kDa trypsin fragment after exposure of the enzyme to ADP-Fe3+ and ascorbate, and of the 48-kDa trypsin fragment after exposure to peroxynitrite. It is concluded that the mitochondrial nicotinamide nucleotide transhydrogenase is sensitive to oxidative stress and that the mechanism underlying this can vary according to the challenge to which the enzyme is exposed. Endogenous ubiquinol may play a role in protecting the enzyme against agents perturbing the lipid phase of the membrane.
Forsmark-Andrée
P
P
Clinical Research Center at NOVUM, Karolinska Institute, Huddinge, Sweden. Patrik.A@biokemi.su.se
Persson
B
B
Radi
R
R
Dallner
G
G
Ernster
L
L
D000244:Adenosine Diphosphate / Q000378:metabolism; D000818:Animals; D001205:Ascorbic Acid / Q000378:metabolism; D015153:Blotting, Western; D002417:Cattle; D005290:Ferric Compounds / Q000378:metabolism; D007700:Kinetics; D008054:Lipid Peroxides / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D009250:NADP Transhydrogenases / Q000378:metabolism*; D009566:Nitrates / Q000378:metabolism; D010084:Oxidation-Reduction; D010449:Peptide Mapping; D013312:Stress, Physiological / Q000378:metabolism; D013367:Submitochondrial Particles / Q000378:metabolism*; D014443:Tyrosine / Q000737:chemistry; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000378:metabolism
D005290:Ferric Compounds; D008054:Lipid Peroxides; D009566:Nitrates; D009243:NAD; D014451:Ubiquinone; C039642:peroxynitric acid; D014443:Tyrosine; D009249:NADP; D000244:Adenosine Diphosphate; D009250:NADP Transhydrogenases; C003741:ubiquinol; D001205:Ascorbic Acid